Role of microbiota short-chain fatty acids in the pathogenesis of autoimmune diseases

Biomed Pharmacother. 2023 Jun:162:114620. doi: 10.1016/j.biopha.2023.114620. Epub 2023 Mar 31.

Abstract

There is emerging evidence that microbiota and its metabolites play an important role in helath and diseases. In this regard, gut microbiota has been found as a crucial component that influences immune responses as well as immune-related disorders such as autoimmune diseases. Gut bacterial dysbiosis has been shown to cause disease and altered microbiota metabolite synthesis, leading to immunological and metabolic dysregulation. Of note, microbiota in the gut produce short-chain fatty acids (SCFAs) such as acetate, butyrate, and propionate, and remodeling in these microbiota metabolites has been linked to the pathophysiology of a number of autoimmune disorders such as type 1 diabetes, multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, celiac disease, and systemic lupus erythematosus. In this review, we will address the most recent findings from the most noteworthy studies investigating the impact of microbiota SCFAs on various autoimmune diseases.

Keywords: GPCRs; HDAC; Microbiota; SCFAs, Autoimmune diseases.

Publication types

  • Review

MeSH terms

  • Autoimmune Diseases*
  • Fatty Acids, Volatile / metabolism
  • Gastrointestinal Microbiome* / physiology
  • Humans
  • Microbiota*
  • Multiple Sclerosis*

Substances

  • Fatty Acids, Volatile